Table 1

Patient characteristics at baseline

Total cohort (n=873)No CVD event (n=774)CVD event (n=99)p Value (CVD versus no CVD)
Age (years), mean±SD54±1453±1462±9<0.001
Sex (female), n (%)574 (66)524 (68)50 (51)0.001
Currently smoking, n (%)272 (31)235 (30)69 (40)0.156
BMI (weight(kg)/height (m²)), mean±SD26±425±426±40.016
Systolic blood pressure (mm Hg), mean±SD146±24145±24153±240.002
Diastolic blood pressure (mm Hg), mean±SD84±1283±1286±110.026
Hypertension, n (%)120 (14)94 (12)26 (26)<0.001
Anti-hypertensives, n (%)134 (15)110 (14)24 (24)0.009
TC (mmol/L), mean±SD5.2±1.25.2±1.25.3±1.40.448
HDL-c, mean±SD1.3±0.31.3±0.31.2±0.30.040
TC:HDL-c ratio, mean±SD4.1±1.04.1±1.04.4±1.00.013
LDL-c, mean±SD3.2±1.13.1±1.03.2±1.20.357
Lipid lowering agents, n (%)30 (3.4)23(3)7 (7)0.035
Diabetes mellitus, n (%)37 (4)29 (4)8 (8)0.044
Family history of CVD, n (%)265 (30)232 (30)33 (33)0.494
Rheumatoid factor (positivity), n (%)654 (75)576 (74)78 (79)0.345
Anti-CCP (positivity), n (%)554 (64)493 (64)61 (62)0.686
DAS28, mean±SD5.0±1.34.9±1.35.4±1.30.001
CRP, median (IQR)14 (2-40)13 (2-38)21 (3-47)0.083
HAQ, median (IQR)0.6 (0.3–1.1)0.6 (0.3–1.1)0.7 (0.3–1.4)0.468
  • Hypertension is defined as multiple measurements of elevated systolic blood pressure (>140 mm Hg) during multiple visits by a physician. Diabetes mellitus includes both type 1 and type 2. All variables represent baseline measures, except when otherwise stated.

  • anti-CCP, anti-cyclic citrullinated peptide; BMI, body mass index; CRP, C-reactive protein; CVD, cardiovascular disease; DAS28, 28-joint disease activity score; HAQ, Health Assessment Questionnaire; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TC, total cholesterol.